Argentum Pharmaceuticals LLC v. Novartis AG

Case Overview & Background

Parties and their roles. Argentum Pharmaceuticals LLC v. Novartis AG (IPR2017-01550) is an inter partes review before the PTAB — an administrative validity challenge, not a district-court infringement suit. Argentum Pharmaceuticals LLC is a New York-based, non-manufacturing generic-drug development company that describes itself as an "evolutionary generic drug company" using "A.I. and vast pharma patent litigation experience to identify and act against flawed pharmaceutical patents" (argentumpharmaceuticals.com). It operates through manufacturing/marketing partnerships — here with KVK-Tech Inc., which was identified as a real party in interest and would be the named ANDA applicant for a generic fingolimod product. Argentum is thus a would-be generic entrant/paragraph-IV-style challenger, not an NPE or university. Novartis AG is the Swiss multinational operating company and patent owner; its U.S. affiliate, Novartis Pharmaceuticals Corporation, markets Gilenya® (fingolimod 0.5 mg capsules), a blockbuster oral therapy for relapsing multiple sclerosis with roughly $3.185 billion in reported 2017 net sales (per Argentum's cert. petition, citing Novartis reporting). Counsel: Argentum was represented by Teresa Stanek Rea, Deborah H. Yellin, and Shannon M. Lentz (Crowell & Moring LLP); Novartis by Jane M. Love, Ph.D., and Robert W. Trenchard (Gibson, Dunn & Crutcher LLP).

Patent, accused technology, and procedural posture. The challenged patent is U.S. Patent No. 9,187,405 B2 ("S1P receptor modulators for treating relapsing-remitting multiple sclerosis," issued Nov. 17, 2015; priority date June 27, 2006; inventors Peter C. Hiestand and Christian Schnell). Its six claims (three independent) are method-of-treatment claims directed to treating relapsing-remitting MS by orally administering fingolimod at a daily 0.5 mg dose "absent an immediately preceding loading dose regimen"; the patent is Orange Book-listed for Gilenya, and the "accused" conduct in the surrounding Hatch-Waxman context is the submission of ANDAs for generic fingolimod 0.5 mg capsules. Argentum filed its petition on June 9, 2017 — a petition substantively identical to the lead petition in Apotex Inc. v. Novartis AG, IPR2017-00854 — and moved to join. On August 9, 2017, the Board (Administrative Patent Judges Lora M. Green, Christopher M. Kaiser, and Robert A. Pollock, with Pollock authoring) instituted review of claims 1–6 on the same three grounds as the Apotex case (obviousness over Kovarik + Thomson; obviousness over Chiba, Kappos 2005, and Budde; anticipation by Kappos 2010) and granted joinder under 35 U.S.C. § 315(c) (IPR2017-01550, Paper 10). Sun Pharma (IPR2017-01929) and Teva/Actavis (IPR2017-01946) were later joined to the same lead case. Because this is an IPR, "venue" is the USPTO's PTAB (headquartered in Alexandria, VA, though proceedings are conducted nationwide), with appeal lying exclusively to the Federal Circuit under 28 U.S.C. § 1295(a)(4)(A); the Board's July 11, 2018 Final Written Decision in IPR2017-00854 (Paper 109) found the claims not unpatentable and denied Novartis's contingent motion to amend as moot. Argentum and the other petitioners appealed (Fed. Cir. Nos. 18-2209, -2230, -2260, -2273, consolidated); after the other appellants settled, the Federal Circuit dismissed Argentum's appeal for lack of Article III standing — Argentum Pharm. LLC v. Novartis Pharm. Corp., 956 F.3d 1374 (Fed. Cir. 2020) (Moore, Lourie, Reyna) — holding that with no ANDA yet filed, and any ANDA to be filed by partner KVK rather than Argentum, the alleged threat of suit and economic harm were speculative. Rehearing was denied (July 9, 2020), and the Supreme Court denied certiorari in No. 20-779 in 2021.

Why the case is notable. The IPR is significant on multiple fronts. First, it involved Gilenya, one of the largest pharmaceutical franchises of its era, and illustrates the strategic value of method-of-use/dosing-regimen claims: even after composition/formulation patents covering Gilenya were invalidated (the PTAB Litigation Blog noted the Federal Circuit had upheld invalidation of a Gilenya composition patent), the '405 patent's low-dose, no-loading-dose method claims survived — the Board found the prior art did not disclose 0.5 mg daily fingolimod without a loading dose and that the art taught away from such a regimen, and the '405 patent was not set to expire until 2027. Second, procedurally it is a textbook example of the joinder pattern under § 315(c), where multiple generic challengers file substantively identical petitions and are folded into a single lead IPR. Third, the Federal Circuit's precedential standing ruling tightened the requirements for IPR appellants, holding that a joint-venture partner that is not the ANDA filer, with no concrete evidence of product-specific investment or imminent suit, lacks injury-in-fact to appeal an adverse final written decision — an important constraint on non-ANDA-filer generic developers. Finally, the surviving claims immediately triggered a wave of Hatch-Waxman ANDA litigation in the District of Delaware (e.g., 18-cv-1038 against Apotex, 18-cv-1039 against Teva, 18-cv-1040 against Sun, 18-cv-1043 against Accord), including preliminary-injunction motion practice — tying the IPR outcome directly to multi-defendant district-court enforcement of the Orange Book-listed dosing claims. One caveat: details of the later district-court dispositions were not fully verified in the available sources, so this overview relies on the PTAB record, the Federal Circuit opinion, and contemporaneous practitioner commentary (PTAB Litigation Blog, RPX Insight, Unified Patents portal).

I'll research this case thoroughly. Note the metadata indicates this is a PTAB IPR proceeding (IPR2017-01550), so I'll also investigate any parallel district court litigation involving the '405 patent.

I have a strong foundation. The metadata concerns a PTAB IPR (not district court infringement litigation), so I'll map the user's requested categories onto the IPR docket plus the related Federal Circuit appeal and parallel district court ANDA cases. Let me dig deeper into the docket events, final written decision, appeal, and parallel district court litigation.

Important framing note

The case in the metadata — Argentum Pharmaceuticals LLC v. Novartis AG, IPR2017-01550 — is not a district court patent infringement suit. It is an inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB) challenging U.S. Patent No. 9,187,405 (the "'405 patent," covering a method of treating relapsing-remitting multiple sclerosis with a 0.5 mg daily dose of fingolimod/Gilenya®). Consequently, there was no complaint, answer, counterclaim, Markman hearing, jury trial, or verdict in the traditional Hatch-Waxman sense. The "litigation" here played out as: (1) the IPR (petition → institution → joinder → final written decision); (2) a Federal Circuit appeal of the PTAB decision; and (3) separate, parallel ANDA district court litigation against other generic filers (not Argentum). Below is the chronological development mapped onto your requested categories.

---

1. Filing & initial pleadings (petition stage)

• 2017-02-03 — Apotex Inc. and Apotex Corp. filed the lead IPR petition in IPR2017-00854, challenging claims 1–6 of the '405 patent on three grounds: (1) obviousness over Kovarik (WO 2006/058316) + Thomson (2006 Core Evidence); (2) obviousness over Chiba (U.S. 6,004,565) + Kappos 2005 + Budde (2002 JASN); (3) anticipation by Kappos 2010 (362 NEJM 387). Argentum Pharm. LLC v. Novartis Pharm. Corp., 956 F.3d 1374, 1376 (Fed. Cir. 2020).
• 2017-06-09 — Argentum filed its IPR Petition (Paper 1) and a concurrent Motion for Joinder (Paper 3) under 35 U.S.C. § 315(c) and 37 C.F.R. § 42.122(b) to join the Apotex IPR. Argentum's petition was "substantively identical" to Apotex's — same claims, same art, same three grounds, same expert declaration (Dr. Barbara Giesser, Ex. 1002), plus one additional exhibit (Ex. 1041, a Federal Circuit decision). See IPR2017-01550, Paper 10, at 4–6; PTACTS petition docs.
• 2017-06-16 — Board issued Notice of Filing Date Accorded (Paper 4).
• 2017-06-29 — Novartis AG filed its Mandatory Notices, Exhibit List, and a Motion for pro hac vice admission of Robert W. Trenchard (Gibson, Dunn & Crutcher; lead counsel Jane M. Love, Ph.D.). Argentum was represented by Teresa Stanek Rea, Deborah H. Yellin, and Shannon Lentz (Crowell & Moring) plus in-house counsel Tyler C. Liu. Novartis did not file a preliminary response to Argentum's petition (due date would have been 2017-09-16).

---

2. Pre-trial motions of substance

• 2017-06-09 (Motion for Joinder, Paper 3) — the key procedural motion. Argentum argued joinder would promote efficiency, raise no new grounds, and not disturb the Apotex trial schedule. Timely because filed within one month of the Apotex institution.
• 2017-08-09 — Decision Instituting IPR and Granting Joinder (Paper 10) — Board (Judges Lora M. Green, Christopher M. Kaiser, Robert A. Pollock; opinion by Pollock) instituted review of claims 1–6 on the same three grounds as IPR2017-00854 and granted Argentum's joinder motion under § 315(c), citing Kyocera Corp. v. SoftView LLC, IPR2013-00004. The Board conditioned joinder on Apotex serving as lead petitioner. After joinder, IPR2017-01550 was administratively terminated/consolidated (Track Docket shows termination date 2017-08-17), and all substantive activity continued in lead case IPR2017-00854.
• Substantive motions in the joined case (IPR2017-00854):
  • 2017-11-13 — Novartis filed its Patent Owner Response (Papers 26/27) and a Contingent Motion to Amend (Paper 28), supported by declarations of Drs. Lublin, Jusko, Schnell, and Steinman (Exs. 2022–2026).
  • 2018-01-11 to 2018-01-22 — Additional discovery dispute: Petitioners sought three documents underlying Dr. Lublin's unexpected-results testimony; Novartis opposed (Paper 38, filed 2018-01-22) under the Garmin standard, and the Board ordered briefing (2018-01-11). This was the most strategically significant discovery fight — it concerned whether the 0.5 mg dose's efficacy in RRMS was truly "unexpected," the linchpin of Novartis's nonobviousness case.
  • 2018-04-19 — Petitioners' Sur-Reply (Paper 85) regarding Novartis's Corrected Contingent Motion to Amend (Paper 61), contesting the proposed amended claims' written-description support and the "subject in need" preamble analysis.
  • Motions to seal and motions to exclude were also litigated and resolved in the FWD (motions to exclude denied; seal motions granted/denied in part).

---

3. Claim construction (Markman analogue)

• The IPR applied the broadest reasonable interpretation (BRI) standard (pre-Phillips framework applicable to IPRs). The Board's Final Written Decision included a claim-interpretation section, notably addressing the "subject in need" / patient-population preamble language of claims 1–6 and the meaning of "treating relapsing-remitting MS" — the parties disputed whether the preamble imported a clinical-efficacy requirement (relevant both to the anticipation/obviousness analysis and to Novartis's contingent motion to amend). No separate Markman proceeding occurred (none is available in IPRs); claim construction was decided as part of the FWD.

---

4. Discovery milestones

• 2017-11-30 — Petitioners served notices of deposition of inventor Christian Schnell and Dr. Fred D. Lublin (Novartis's lead clinical expert).
• 2017-12-15 — Dr. Lublin deposed (per Novartis's opposition brief, Paper 38).
• 2018-01 — Petitioners' request for additional discovery of Lublin-related documents (see above); Novartis opposed under the Garmin "helpfulness" standard; Board ordered briefing and resolved.
• Expert discovery was otherwise driven by declarations: Petitioners relied on Dr. Barbara Giesser (Pet. Ex. 1002) and reply expert Dr. Leslie Z. Benet (Ex. 1047); Novartis relied on Drs. Fred D. Lublin, William J. Jusko, Christian Schnell, and Lawrence Steinman.

---

5. Trial events, "verdict," and post-trial motions

• 2018-05-11 — Oral argument held before the Board in the joined proceeding (transcript entered as Paper 108).
• 2018-07-11 — Final Written Decision (IPR2017-00854, Paper 109) (panel: Kaiser, Pollock, Sawert — Green had left the Board; opinion by Pollock). The Board held that Petitioners failed to prove, by a preponderance of the evidence, that claims 1–6 of the '405 patent are unpatentable on any of the three grounds (Kovarik+Thomson; Chiba+Kappos 2005+Budde; Kappos 2010), crediting Novartis's unexpected-results and dosage-safety evidence. The Corrected Contingent Motion to Amend was denied as moot; motions to exclude were denied; seal motions disposed. The FWD was entered on the IPR2017-01550 docket on 2018-08-07.
• 2018-07-27 — Petitioners (Apotex, Argentum, Teva/Actavis, Sun) filed a Notice of Appeal (Paper 111) to the Federal Circuit.

---

6. Appeal, settlement, and final disposition

• Appeals consolidated: Federal Circuit Appeal Nos. 2018-2209 (Apotex), 2018-2230 (Sun), 2018-2260 (Teva/Actavis), and 2018-2273 (Argentum) — all appealing the same FWD. 956 F.3d at 1376.
• 2018-08-29 — Novartis moved to dismiss Argentum's appeal for lack of Article III standing (before opening briefs).
• 2018-09-10 — Argentum opposed, submitting declarations of CEO Jeffrey Gardner and KVK-Tech CEO Anthony Tabasso regarding the planned generic Gilenya® ANDA and investment losses.
• Settlements during appeal: Teva and Actavis settled before argument (No. 18-2260 dismissed); Sun settled (No. 18-2230 dismissed); Apotex settled after argument (No. 18-2209 dismissed). This left Argentum as the sole appellant — which Novartis flagged in a Fed. R. App. P. 28(j) notice making standing a threshold jurisdictional issue. 956 F.3d at 1377–78.
• *2020-04-23 — Federal Circuit decision: Argentum Pharms. LLC v. Novartis Pharms. Corp., 956 F.3d 1374 (Fed. Cir. 2020)* (Lourie, Moore, Reyna; Moore, J.). The panel dismissed Argentum's appeal for lack of Article III standing, without reaching the merits of the Board's validity ruling. The court rejected all three asserted injuries-in-fact: (1) no ANDA had been filed, and any ANDA would be filed by KVK-Tech, not Argentum, so the infringement-suit threat was not personal/imminent (distinguishing Altaire Pharms. v. Paragon Bioteck, 889 F.3d 1274); (2) alleged economic losses were speculative and not tied specifically to a Gilenya® product; (3) IPR estoppel does not independently confer standing. Costs awarded to Novartis.
• 2020-06-08 — Argentum filed a petition for panel rehearing and rehearing en banc, arguing the panel erred on injury-in-fact for a joint-venture partner facing imminent suit. (I do not have a confirmed public docket entry for the en banc denial date; the panel decision in 956 F.3d 1374 stands as the operative final disposition.)

Final posture: The PTAB's FWD — claims 1–6 of the '405 patent upheld as not shown unpatentable — is final as to Argentum; its appeal was dismissed on standing grounds, and the merits of the FWD were never reviewed by the Federal Circuit. The '405 patent remained in force (Orange Book expiry listed as 2027).

---

7. Parallel PTAB IPR/PGR proceedings and their effect

• IPR2017-00854 (Apotex, lead case) — instituted 2017-07-18; joined cases: IPR2017-01550 (Argentum), IPR2017-01929 (Sun), and IPR2017-01946 (Teva/Actavis) — all granted joinder on substantively identical petitions. The single FWD (2018-07-11) governed all joined petitioners.
• IPR2014-00784 (Torrent Pharm. Ltd. v. Novartis AG) — an earlier, related IPR on U.S. Patent No. 8,324,283 (fingolimod compositions); the Board's FWD there was affirmed by the Federal Circuit on 2017-04-12 (Argentum cited it as Ex. 1041). It was referenced in the FWD's background and informed the parties' arguments on fingolimod prior art and nonobviousness.
• Effect on district court litigation: There was no co-pending district court case against Argentum (it never filed an ANDA — the very fact that defeated its appellate standing). But the successful FWD prompted new ANDA litigation: according to contemporaneous commentary (PTAB Litigation Blog, July 2018), "Shortly thereafter [the FWD], Novartis filed suit" against generic ANDA filers on the '405 patent — part of the broader Gilenya® enforcement campaign referenced in Argentum's briefing (Novartis had sued "each and every competitor" seeking generic approval, and obtained injunctions and 30-month stays). I could not confirm the exact district court docket numbers from my sources, so those case numbers should be verified separately if needed.

---

Key takeaway

This matter is best understood as a successful defensive IPR outcome for Novartis followed by a procedural win on appeal: the PTAB upheld the '405 patent against all three validity challenges (FWD 2018-07-11, Paper 109), and the Federal Circuit never reached the merits because Argentum — the last remaining appellant after its co-petitioners settled — could not establish Article III standing without a filed ANDA (Argentum, 956 F.3d 1374, decided 2020-04-23). Argentum's challenge therefore ended with no invalidation and no merits appellate review, and costs were assessed against it.

Threshold clarification

This matter is not a district-court patent infringement case — it is an inter partes review (IPR2017-01550) before the PTAB, captioned Argentum Pharmaceuticals LLC v. Novartis AG. There is therefore no "plaintiff"; the functional equivalent is petitioner Argentum Pharmaceuticals LLC (a would-be generic entrant partnered with KVK-Tech, Inc., the ANDA filer). The counsel below are the attorneys of record for Argentum in the IPR and in the related Federal Circuit appeal (Argentum Pharm. LLC v. Novartis Pharm. Corp., 956 F.3d 1374 (Fed. Cir. 2020), consolidated Nos. 18-2209, -2230, -2260, -2273) and certiorari proceeding (No. 20-779). No local-counsel concept exists at the PTAB, and nothing in the docket is sealed.

Counsel of record for petitioner Argentum Pharmaceuticals LLC

Supporting record

• Power of Attorney (Paper 2, filed June 9, 2017): Argentum appointed "the Practitioners associated with PTO Customer Number 23911 (Crowell & Moring LLP) and Tyler C. Liu (Reg. 72,126, Argentum Pharmaceuticals LLC) as its attorneys … including the appointment of lead and backup counsel," signed by Argentum's Jeffrey R. Gardner (a company officer, not counsel).
• Notice of Filing Date Accorded to Petition (Paper 4, June 16, 2017): lists petitioner's counsel as Teresa Stanek Rea, Deborah H. Yellin, Shannon M. Lentz (Crowell & Moring), and Tyler C. Liu (Argentum).
• Novartis's mandatory notices and PHV motion (Papers 7–9, June 29, 2017): service certifications identify the same four as "counsel of record for Petitioner."
• Federal Circuit opinion (956 F.3d 1374): identifies Rea (argued) and Yellin (on brief) for appellant Argentum in the consolidated appeal of the Board's Final Written Decision in IPR2017-00854 (with which IPR2017-01550 was joined).
• Institution/joinder decision (Paper 10, Aug. 9, 2017): Board (APJs Green, Kaiser, Pollock; Pollock authoring) instituted review of claims 1–6 and granted Argentum's § 315(c) joinder into lead case IPR2017-00854, where Apotex (represented separately by Wilson Sonsini) took the lead role.

Caveats

• I could not retrieve Argentum's own Petitioner Mandatory Notices paper to quote the formal "lead/backup" designation line-by-line; the lead-counsel designation of Rea is instead confirmed by the Federal Circuit opinion, the rehearing petition ("oral argument … was led by Argentum's lead counsel"), and Law360's reporting.
• The Supreme Court reply brief in No. 20-779 appears to list at least one additional Crowell attorney (snippet captured only "Deborah Yellin; Ali H.K. …"); the full name was not verifiable in the available sources and is therefore omitted rather than guessed.
• Patent owner's counsel — for completeness: Jane M. Love, Ph.D. (lead) and Robert W. Trenchard (backup, pro hac vice), Gibson, Dunn & Crutcher LLP, 200 Park Avenue, New York, NY — represented Novartis; Love argued at the Federal Circuit.

Counsel of record for the "defendant" (Novartis) in IPR2017-01550

Terminology note first. This case is an inter partes review before the PTAB, not a district-court infringement suit, so there are no "plaintiffs/defendants" in the traditional sense — the parties are Petitioner (Argentum Pharmaceuticals LLC) and Patent Owner/Respondent (Novartis AG, the "defendant" per the case metadata). The counsel of record below represent Novartis in its capacity as Patent Owner before the Board, and later as Appellee at the Federal Circuit. The only "defendant" in this proceeding is Novartis AG; there are no other defendants.

Lead counsel

Jane M. Love, Ph.D.

• Role: Lead counsel for Patent Owner (USPTO Reg. No. 42,812) — the registered practitioner required by 37 C.F.R. § 42.10(a) to serve as lead in a PTAB trial.
• Firm/office: Gibson, Dunn & Crutcher LLP, 200 Park Avenue, 47th Floor, New York, NY 10166.
• Source: Patent Owner's Mandatory Notices, IPR2017-01550, Paper 9 (filed June 29, 2017), designating Love as lead counsel; identical designation in the lead case, IPR2017-00854, Paper 4 (Apr. 11, 2017), and the updated notice, Paper 22 (Sept. 5, 2017).
• Experience note: Ph.D. in molecular biology (Univ. of Pennsylvania); Fordham Law; lead trial counsel for Novartis on the Gilenya® franchise and named a Law360 2017 Life Sciences MVP for defending the MS drug "from a multi-front attack" (Law360, Dec. 18, 2017). She argued the oral argument in the joined IPR (IPR2017-00854, Paper 108, hearing transcript of May 11, 2018) and argued the subsequent Federal Circuit appeal in Argentum Pharm. LLC v. Novartis Pharm. Corp., 956 F.3d 1374 (Fed. Cir. 2020) ("JANE M. LOVE, Gibson, Dunn & Crutcher LLP, New York, NY, argued for appellee.").

Backup counsel

Robert W. Trenchard

• Role: Back-up counsel for Patent Owner, admitted pro hac vice (motion filed June 29, 2017, with supporting declaration Ex. 2001, in IPR2017-01550; 22 years of litigation experience at the time, NY and NJ bars, admitted in the Third, Seventh, and D.C. Circuits, and multiple federal district courts).
• Firm/office: Gibson, Dunn & Crutcher LLP, 200 Park Avenue, 47th Floor, New York, NY 10166.
• Source: Patent Owner's Mandatory Notices (Paper 9, IPR2017-01550) listing Trenchard as back-up counsel; Motion for Admission Pro Hac Vice (June 29, 2017) with Trenchard Decl. (Ex. 2001); hearing transcript (IPR2017-00854, Paper 108) showing him appearing for Patent Owner; Federal Circuit opinion listing him as co-counsel for appellee, 956 F.3d at 1375.
• Experience note: Gibson Dunn litigation partner (Harvard Law 1994; SDNY clerk to Judge Lewis A. Kaplan). His firm bio confirms he "co-led the team with partner Dr. Jane Love" representing Novartis in the successful IPR on the Gilenya dosing method-of-use patent and the ensuing Delaware ANDA litigation against 23 generic filers, including the preliminary injunction obtained from the bench after a one-day evidentiary hearing. His declaration in this very case notes prior Novartis/Gilenya district-court work in the District of New Jersey (e.g., against Actavis Elizabeth and Apotex).

Other attorneys who appeared (not designated counsel of record)

• Andrew Blythe (Gibson Dunn, New York) appeared on behalf of the Patent Owner at the May 11, 2018 oral hearing in the joined lead case (IPR2017-00854, Paper 108 — hearing transcript listing "JANE M. LOVE, ESQUIRE; ROBERT W. TRENCHARD, ESQUIRE; ANDREW BLYTHE, ESQUIRE"). He was not listed in the mandatory-notice counsel designations in IPR2017-01550 (Paper 9) or IPR2017-00854 (Papers 4/22), so he was not formally added as back-up counsel of record under 37 C.F.R. § 42.8(b)(3), but he is on the hearing record.
• Novartis in-house attendees (not counsel of record — no in-house attorney signed PTAB filings; the power of attorney ran to Gibson Dunn): Peter Waibel (U.S. Head of Patent Litigation, Novartis), Drew Holmes (Novartis U.S.), and Conrad Arlander (Novartis, Basel) attended the May 11, 2018 hearing per the transcript.

Additional context / caveats

• No local counsel was required or designated; PTAB practice uses lead/back-up counsel rather than local counsel, and Gibson Dunn's New York office handled the entire proceeding (no Washington, D.C. or Alexandria-based attorney of record for Novartis).
• Post-joinder continuity: After IPR2017-01550 was joined into IPR2017-00854 (Paper 10, Aug. 9, 2017) and terminated as a standalone case, Love and Trenchard continued as Novartis's counsel of record in the lead case through the Final Written Decision (Paper 109, July 11, 2018) and on appeal (Fed. Cir. No. 18-2273, consolidated; dismissed for lack of standing, 956 F.3d 1374). The Court's opinion lists only Love and Trenchard for the appellee.
• District-court "defendants" are a different matter: The downstream Hatch-Waxman suits (D. Del. 18-cv-1038/1039/1040/1043) are cases where Novartis is the plaintiff and the generic companies (Apotex, Teva, Sun, Accord) are the defendants — not part of the IPR docket. Counsel for those defendants (e.g., Wilson Sonsini, Kirkland, Winston & Strawn) are not counsel of record in IPR2017-01550 and are not included above.

Bottom line: For Novartis AG (patent owner/respondent, i.e., the "defendant" in the metadata), the formal counsel of record in IPR2017-01550 were Jane M. Love, Ph.D. (lead) and Robert W. Trenchard (back-up, pro hac vice), both of Gibson, Dunn & Crutcher LLP's New York office — the same duo that litigated the joined lead IPR and the Federal Circuit appeal. No filings in this IPR are sealed that would conceal additional counsel; the mandatory notices are public and complete.